Treatment with the topical JAK inhibitor reduced abscess and inflammatory nodules in a phase 2 randomized, controlled trial in patients with mild hidradenitis suppurativa.
Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.
Intravenous nipocalimab provides clinical benefits for patients with generalized myasthenia gravis, an IgG autoantibody-mediated disease characterized by muscle weakness.
Currently, the tumor necrosis factor inhibitor adalimumab is the only biologic therapy approved for the treatment of moderate to severe hidradenitis suppurativa.